PHARMING GROUP NV (PHARM.AS) Stock Fundamental Analysis
Europe - AMS:PHARM - NL0010391025 - Common Stock
1.395 EUR
+0.03 (+1.97%)
Taking everything into account, PHARM scores 5 out of 10 in our fundamental rating. PHARM was compared to 76 industry peers in the Biotechnology industry. PHARM has an average financial health and profitability rating. PHARM has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
PHARM had negative earnings in the past year.
PHARM had a positive operating cash flow in the past year.
In multiple years PHARM reported negative net income over the last 5 years.
In multiple years PHARM reported negative operating cash flow during the last 5 years.
1.2 Ratios
PHARM has a better Return On Assets (-1.84%) than 73.68% of its industry peers.
The Return On Equity of PHARM (-3.42%) is better than 77.63% of its industry peers.
PHARM has a Return On Invested Capital of 5.13%. This is amongst the best in the industry. PHARM outperforms 82.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.84% | ||
| ROE | -3.42% | ||
| ROIC | 5.13% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of PHARM (7.21%) is better than 80.26% of its industry peers.
PHARM has a better Gross Margin (89.31%) than 81.58% of its industry peers.
In the last couple of years the Gross Margin of PHARM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.21% | ||
| PM (TTM) | N/A | ||
| GM | 89.31% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
PHARM has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for PHARM has been increased compared to 1 year ago.
Compared to 5 years ago, PHARM has more shares outstanding
The debt/assets ratio for PHARM has been reduced compared to a year ago.
2.2 Solvency
PHARM has an Altman-Z score of 0.86. This is a bad value and indicates that PHARM is not financially healthy and even has some risk of bankruptcy.
PHARM has a Altman-Z score (0.86) which is comparable to the rest of the industry.
PHARM has a debt to FCF ratio of 4.26. This is a neutral value as PHARM would need 4.26 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.26, PHARM belongs to the top of the industry, outperforming 81.58% of the companies in the same industry.
A Debt/Equity ratio of 0.50 indicates that PHARM is not too dependend on debt financing.
The Debt to Equity ratio of PHARM (0.50) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.26 | ||
| Altman-Z | 0.86 |
ROIC/WACC0.89
WACC5.76%
2.3 Liquidity
PHARM has a Current Ratio of 2.79. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
PHARM has a Current ratio (2.79) which is comparable to the rest of the industry.
A Quick Ratio of 2.07 indicates that PHARM has no problem at all paying its short term obligations.
PHARM has a Quick ratio (2.07) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.07 |
3. Growth
3.1 Past
PHARM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.30%, which is quite impressive.
The Revenue has grown by 21.15% in the past year. This is a very strong growth!
Measured over the past years, PHARM shows a quite strong growth in Revenue. The Revenue has been growing by 10.64% on average per year.
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
3.2 Future
Based on estimates for the next years, PHARM will show a very strong growth in Earnings Per Share. The EPS will grow by 61.94% on average per year.
The Revenue is expected to grow by 9.43% on average over the next years. This is quite good.
EPS Next Y308.75%
EPS Next 2Y134.62%
EPS Next 3Y79.43%
EPS Next 5Y61.94%
Revenue Next Year18.75%
Revenue Next 2Y15.45%
Revenue Next 3Y15.46%
Revenue Next 5Y9.43%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Forward Earnings ratio of 25.50, PHARM can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, PHARM is valued cheaply inside the industry as 84.21% of the companies are valued more expensively.
PHARM's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 32.68.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.5 |
4.2 Price Multiples
PHARM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PHARM is cheaper than 97.37% of the companies in the same industry.
98.68% of the companies in the same industry are more expensive than PHARM, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.66 | ||
| EV/EBITDA | 1.9 |
4.3 Compensation for Growth
PHARM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PHARM's earnings are expected to grow with 79.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y134.62%
EPS Next 3Y79.43%
5. Dividend
5.1 Amount
PHARM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMS:PHARM (11/7/2025, 7:00:00 PM)
1.395
+0.03 (+1.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners14.71%
Inst Owner ChangeN/A
Ins Owners1.38%
Ins Owner ChangeN/A
Market Cap95.58M
Revenue(TTM)297.20M
Net Income(TTM)-8.20M
Analysts87.69
Price Target1.95 (39.78%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.45%
Min EPS beat(2)-42.39%
Max EPS beat(2)123.3%
EPS beat(4)2
Avg EPS beat(4)19%
Min EPS beat(4)-42.39%
Max EPS beat(4)123.3%
EPS beat(8)3
Avg EPS beat(8)-53.99%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)11.02%
Min Revenue beat(2)8.68%
Max Revenue beat(2)13.37%
Revenue beat(4)3
Avg Revenue beat(4)6.98%
Min Revenue beat(4)-5.54%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)2.17%
Revenue beat(12)6
Avg Revenue beat(12)-0.82%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-69.24%
PT rev (3m)-68.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)96.67%
EPS NY rev (1m)0%
EPS NY rev (3m)88.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.5 | ||
| P/S | 0.32 | ||
| P/FCF | 3.66 | ||
| P/OCF | 3.55 | ||
| P/B | 0.46 | ||
| P/tB | 1.06 | ||
| EV/EBITDA | 1.9 |
EPS(TTM)0
EYN/A
EPS(NY)0.05
Fwd EY3.92%
FCF(TTM)0.38
FCFY27.33%
OCF(TTM)0.39
OCFY28.17%
SpS4.3
BVpS3.03
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.84% | ||
| ROE | -3.42% | ||
| ROCE | 6.84% | ||
| ROIC | 5.13% | ||
| ROICexc | 7.92% | ||
| ROICexgc | 19.07% | ||
| OM | 7.21% | ||
| PM (TTM) | N/A | ||
| GM | 89.31% | ||
| FCFM | 8.87% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score6
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.26 | ||
| Debt/EBITDA | 2.95 | ||
| Cap/Depr | 5.84% | ||
| Cap/Sales | 0.27% | ||
| Interest Coverage | 3.72 | ||
| Cash Conversion | 77.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.07 | ||
| Altman-Z | 0.86 |
F-Score6
WACC5.76%
ROIC/WACC0.89
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
EPS Next Y308.75%
EPS Next 2Y134.62%
EPS Next 3Y79.43%
EPS Next 5Y61.94%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
Revenue Next Year18.75%
Revenue Next 2Y15.45%
Revenue Next 3Y15.46%
Revenue Next 5Y9.43%
EBIT growth 1Y248.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year279.47%
EBIT Next 3Y79.88%
EBIT Next 5Y88.46%
FCF growth 1Y288.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y313.32%
OCF growth 3YN/A
OCF growth 5YN/A
PHARMING GROUP NV / PHARM.AS FAQ
What is the ChartMill fundamental rating of PHARMING GROUP NV (PHARM.AS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PHARM.AS.
Can you provide the valuation status for PHARMING GROUP NV?
ChartMill assigns a valuation rating of 6 / 10 to PHARMING GROUP NV (PHARM.AS). This can be considered as Fairly Valued.
Can you provide the profitability details for PHARMING GROUP NV?
PHARMING GROUP NV (PHARM.AS) has a profitability rating of 4 / 10.
Can you provide the financial health for PHARM stock?
The financial health rating of PHARMING GROUP NV (PHARM.AS) is 5 / 10.
What is the earnings growth outlook for PHARMING GROUP NV?
The Earnings per Share (EPS) of PHARMING GROUP NV (PHARM.AS) is expected to grow by 308.75% in the next year.